Bitsiklol tablets 25 mg №18

Description for Bitsiklol tablets 25 mg №18

Pharmacological properties: Myramistin, used to treat liver diseases. On chemical structure similar to bifendatu. Application Bitsiklola reduces elevated transaminase activity in hepatitis, liver damage by chloroform, D-galactosamine and paracetamol, the normalization of the structure of hepatic tissue disorders of varying severity. Bitsiklol inhibits production of tumor necrosis factor (TNF-α) activity of neutrophil granulocytes, Kupffer cells and macrophages, as well as promotes the removal of the cells of free radicals. Thus, the inhibits Bitsiklol oxidative stress caused by the dysfunction of mitochondria, which prevents apoptosis and necrosis of hepatocytes. Also inhibits apoptosis Bitsiklol hepatocytes stimulated with TNF-α and cytotoxic T cells, leading to the restoration of damaged DNA and the nucleus of hepatocytes.
Bitsiklol also significantly inhibits the expression of HBsAg and HBeAg, and significantly reduces the DNA of hepatitis B virus and hepatitis C virus RNA levels in chronic viral hepatitis B and C.
The half-life of alpha phase is 0.84 h, in the final phase - 6.26 h, the time to reach maximum plasma concentration is 1.8 h, the maximum concentration - 50 ng / ml. The maximum concentration and AUC are directly dependent on the dose of the drug, but other pharmacokinetic parameters were dose-dependent change is insignificant.
The drug does not accumulates in the body after repeated taking in normal doses. The maximum concentration in serum can be increased while taking the drug after meals. Bitsiklola metabolism in the liver, with the participation of cytochrome P450, with the formation of major metabolites - 4OH-bitsiklola and 4ON-bitsiklola.
The drug is determined in the blood in unchanged 15 min after oral administration. The maximum concentration in the liver bitsiklola achieved within 4 h after dosing. The degree of binding to plasma proteins is 78%. Less than 30% bitsiklola excreted in the feces within 24 h. About 1.3% of the drug excreted in the urine, 0.03% - in the bile.

Indications: Chronic hepatitis of various etiologies (viral, toxic, alcohol).

USE: Adults and children aged 12 and over, was appointed interior, 25 mg three times a day. In some cases, the dose may be increased to 50 mg 3 times a day: in the treatment of chronic hepatitis C, an uncontrolled increase in transaminase levels or absence of significant positive dynamics of the level of ALT and AsAT for 1-2 months receiving Bitsiklola a dose of 25 mg 3 times day, with liver cirrhosis, fatty liver, alcoholic hepatitis, while receiving nucleoside reverse transcriptase inhibitors (lamivudine). Bitsiklol should preferably be taken within 2 hours after meals. The minimum duration of treatment - 6 months. When necessary, treatment can be repeated after 1 month.

CONTRAINDICATIONS: Hypersensitivity to the drug, acute hepatitis, pregnancy and breast-feeding, the age of 12 years.

SIDE EFFECTS: generally well tolerated, and in rare cases can be observed skin rash and dizziness.

SPECIAL INSTRUCTIONS: In the period of treatment should be monitored clinical picture and liver function.
Bitsiklol with caution in patients with decompensated liver function (hypoalbuminemia, cirrhosis, esophageal varices, hepatic encephalopathy, a severe form of hepatitis). It should be used with caution in patients with autoimmune hepatitis.
Precautions should be used in the management of vehicles and dealing with potentially dangerous machinery.

INTERACTION: when taken with nucleoside reverse transcriptase inhibitors (lamivudine) may decrease the effectiveness of Bitsiklola.

Overdose: If you receive Bitsiklola 150 mg 3 times a day no side effects were observed. In addition, the excess of the usual human dose is 400 times did not cause intoxication.

Storage: in dry place at 8-25 ° C.